世界の原発性免疫不全薬市場予測2023-2029:サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤

【英語タイトル】Primary Immunodeficiency Drugs Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料(MMG23LY8603)・商品コード:MMG23LY8603
・発行会社(調査会社):Market Monitor Global
・発行日:2023年7月
・ページ数:73
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野:医薬品&ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥494,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD4,225 ⇒換算¥642,200見積依頼/購入/質問フォーム
Enterprise User(閲覧人数制限なし)USD4,875 ⇒換算¥741,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の原発性免疫不全薬市場規模と予測を収録しています。・世界の原発性免疫不全薬市場:売上、2018年-2023年、2024年-2029年
・世界の原発性免疫不全薬市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の原発性免疫不全薬市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「サイトカイン」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

原発性免疫不全薬のグローバル主要企業は、ADMA Biologics, Inc.、 CSL Behring, LLC、 Octapharma、 Takeda Pharmaceutical Company、 Grifols Biologicals, Inc.、 Baxter、 Kedrion Biopharma、 BPL Inc.、 Pharming Group、 Shire、 Chengdu Rongsheng Pharmaceutical Co., Ltdなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、原発性免疫不全薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の原発性免疫不全薬市場:タイプ別、2018年-2023年、2024年-2029年
世界の原発性免疫不全薬市場:タイプ別市場シェア、2022年
・サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤

世界の原発性免疫不全薬市場:用途別、2018年-2023年、2024年-2029年
世界の原発性免疫不全薬市場:用途別市場シェア、2022年
・病院、専門クリニック、その他

世界の原発性免疫不全薬市場:地域・国別、2018年-2023年、2024年-2029年
世界の原発性免疫不全薬市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における原発性免疫不全薬のグローバル売上、2018年-2023年
・主要企業における原発性免疫不全薬のグローバル売上シェア、2022年
・主要企業における原発性免疫不全薬のグローバル販売量、2018年-2023年
・主要企業における原発性免疫不全薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
ADMA Biologics, Inc.、 CSL Behring, LLC、 Octapharma、 Takeda Pharmaceutical Company、 Grifols Biologicals, Inc.、 Baxter、 Kedrion Biopharma、 BPL Inc.、 Pharming Group、 Shire、 Chengdu Rongsheng Pharmaceutical Co., Ltd

*************************************************************

・調査・分析レポートの概要
原発性免疫不全薬市場の定義
市場セグメント
世界の原発性免疫不全薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の原発性免疫不全薬市場規模
世界の原発性免疫不全薬市場規模:2022年 VS 2029年
世界の原発性免疫不全薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの原発性免疫不全薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の原発性免疫不全薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤
原発性免疫不全薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:病院、専門クリニック、その他
原発性免疫不全薬の用途別グローバル売上・予測

・地域別市場分析
地域別原発性免疫不全薬市場規模 2022年と2029年
地域別原発性免疫不全薬売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
ADMA Biologics, Inc.、 CSL Behring, LLC、 Octapharma、 Takeda Pharmaceutical Company、 Grifols Biologicals, Inc.、 Baxter、 Kedrion Biopharma、 BPL Inc.、 Pharming Group、 Shire、 Chengdu Rongsheng Pharmaceutical Co., Ltd
...

Drugs for the treatment of primary immunodeficiency diseases
This report aims to provide a comprehensive presentation of the global market for Primary Immunodeficiency Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Immunodeficiency Drugs. This report contains market size and forecasts of Primary Immunodeficiency Drugs in global, including the following market information:
Global Primary Immunodeficiency Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Primary Immunodeficiency Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Primary Immunodeficiency Drugs companies in 2022 (%)
The global Primary Immunodeficiency Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Cytokines Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Primary Immunodeficiency Drugs include ADMA Biologics, Inc., CSL Behring, LLC, Octapharma, Takeda Pharmaceutical Company, Grifols Biologicals, Inc., Baxter, Kedrion Biopharma, BPL Inc. and Pharming Group, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Primary Immunodeficiency Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Primary Immunodeficiency Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Primary Immunodeficiency Drugs Market Segment Percentages, by Type, 2022 (%)
Cytokines
Anti Cytokine Antibodies
Signal Molecule Inhibitor
Global Primary Immunodeficiency Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Primary Immunodeficiency Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Specialist Clinic
Othere
Global Primary Immunodeficiency Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Primary Immunodeficiency Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Primary Immunodeficiency Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Primary Immunodeficiency Drugs revenues share in global market, 2022 (%)
Key companies Primary Immunodeficiency Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Primary Immunodeficiency Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
ADMA Biologics, Inc.
CSL Behring, LLC
Octapharma
Takeda Pharmaceutical Company
Grifols Biologicals, Inc.
Baxter
Kedrion Biopharma
BPL Inc.
Pharming Group
Shire
Chengdu Rongsheng Pharmaceutical Co., Ltd
Outline of Major Chapters:
Chapter 1: Introduces the definition of Primary Immunodeficiency Drugs, market overview.
Chapter 2: Global Primary Immunodeficiency Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Primary Immunodeficiency Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Primary Immunodeficiency Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Primary Immunodeficiency Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Primary Immunodeficiency Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Primary Immunodeficiency Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Primary Immunodeficiency Drugs Overall Market Size
2.1 Global Primary Immunodeficiency Drugs Market Size: 2022 VS 2029
2.2 Global Primary Immunodeficiency Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Primary Immunodeficiency Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Primary Immunodeficiency Drugs Players in Global Market
3.2 Top Global Primary Immunodeficiency Drugs Companies Ranked by Revenue
3.3 Global Primary Immunodeficiency Drugs Revenue by Companies
3.4 Global Primary Immunodeficiency Drugs Sales by Companies
3.5 Global Primary Immunodeficiency Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Primary Immunodeficiency Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Primary Immunodeficiency Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Primary Immunodeficiency Drugs Players in Global Market
3.8.1 List of Global Tier 1 Primary Immunodeficiency Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Primary Immunodeficiency Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Primary Immunodeficiency Drugs Market Size Markets, 2022 & 2029
4.1.2 Cytokines
4.1.3 Anti Cytokine Antibodies
4.1.4 Signal Molecule Inhibitor
4.2 By Type – Global Primary Immunodeficiency Drugs Revenue & Forecasts
4.2.1 By Type – Global Primary Immunodeficiency Drugs Revenue, 2018-2023
4.2.2 By Type – Global Primary Immunodeficiency Drugs Revenue, 2024-2029
4.2.3 By Type – Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Primary Immunodeficiency Drugs Sales & Forecasts
4.3.1 By Type – Global Primary Immunodeficiency Drugs Sales, 2018-2023
4.3.2 By Type – Global Primary Immunodeficiency Drugs Sales, 2024-2029
4.3.3 By Type – Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Primary Immunodeficiency Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Primary Immunodeficiency Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Specialist Clinic
5.1.4 Othere
5.2 By Application – Global Primary Immunodeficiency Drugs Revenue & Forecasts
5.2.1 By Application – Global Primary Immunodeficiency Drugs Revenue, 2018-2023
5.2.2 By Application – Global Primary Immunodeficiency Drugs Revenue, 2024-2029
5.2.3 By Application – Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Primary Immunodeficiency Drugs Sales & Forecasts
5.3.1 By Application – Global Primary Immunodeficiency Drugs Sales, 2018-2023
5.3.2 By Application – Global Primary Immunodeficiency Drugs Sales, 2024-2029
5.3.3 By Application – Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Primary Immunodeficiency Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Primary Immunodeficiency Drugs Market Size, 2022 & 2029
6.2 By Region – Global Primary Immunodeficiency Drugs Revenue & Forecasts
6.2.1 By Region – Global Primary Immunodeficiency Drugs Revenue, 2018-2023
6.2.2 By Region – Global Primary Immunodeficiency Drugs Revenue, 2024-2029
6.2.3 By Region – Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Primary Immunodeficiency Drugs Sales & Forecasts
6.3.1 By Region – Global Primary Immunodeficiency Drugs Sales, 2018-2023
6.3.2 By Region – Global Primary Immunodeficiency Drugs Sales, 2024-2029
6.3.3 By Region – Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Primary Immunodeficiency Drugs Revenue, 2018-2029
6.4.2 By Country – North America Primary Immunodeficiency Drugs Sales, 2018-2029
6.4.3 US Primary Immunodeficiency Drugs Market Size, 2018-2029
6.4.4 Canada Primary Immunodeficiency Drugs Market Size, 2018-2029
6.4.5 Mexico Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Primary Immunodeficiency Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Primary Immunodeficiency Drugs Sales, 2018-2029
6.5.3 Germany Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.4 France Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.5 U.K. Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.6 Italy Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.7 Russia Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.9 Benelux Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Primary Immunodeficiency Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Primary Immunodeficiency Drugs Sales, 2018-2029
6.6.3 China Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.4 Japan Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.5 South Korea Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.7 India Primary Immunodeficiency Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Primary Immunodeficiency Drugs Revenue, 2018-2029
6.7.2 By Country – South America Primary Immunodeficiency Drugs Sales, 2018-2029
6.7.3 Brazil Primary Immunodeficiency Drugs Market Size, 2018-2029
6.7.4 Argentina Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Primary Immunodeficiency Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Primary Immunodeficiency Drugs Sales, 2018-2029
6.8.3 Turkey Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8.4 Israel Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8.6 UAE Primary Immunodeficiency Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 ADMA Biologics, Inc.
7.1.1 ADMA Biologics, Inc. Company Summary
7.1.2 ADMA Biologics, Inc. Business Overview
7.1.3 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Major Product Offerings
7.1.4 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.1.5 ADMA Biologics, Inc. Key News & Latest Developments
7.2 CSL Behring, LLC
7.2.1 CSL Behring, LLC Company Summary
7.2.2 CSL Behring, LLC Business Overview
7.2.3 CSL Behring, LLC Primary Immunodeficiency Drugs Major Product Offerings
7.2.4 CSL Behring, LLC Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.2.5 CSL Behring, LLC Key News & Latest Developments
7.3 Octapharma
7.3.1 Octapharma Company Summary
7.3.2 Octapharma Business Overview
7.3.3 Octapharma Primary Immunodeficiency Drugs Major Product Offerings
7.3.4 Octapharma Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Octapharma Key News & Latest Developments
7.4 Takeda Pharmaceutical Company
7.4.1 Takeda Pharmaceutical Company Company Summary
7.4.2 Takeda Pharmaceutical Company Business Overview
7.4.3 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Major Product Offerings
7.4.4 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Takeda Pharmaceutical Company Key News & Latest Developments
7.5 Grifols Biologicals, Inc.
7.5.1 Grifols Biologicals, Inc. Company Summary
7.5.2 Grifols Biologicals, Inc. Business Overview
7.5.3 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Major Product Offerings
7.5.4 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Grifols Biologicals, Inc. Key News & Latest Developments
7.6 Baxter
7.6.1 Baxter Company Summary
7.6.2 Baxter Business Overview
7.6.3 Baxter Primary Immunodeficiency Drugs Major Product Offerings
7.6.4 Baxter Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Baxter Key News & Latest Developments
7.7 Kedrion Biopharma
7.7.1 Kedrion Biopharma Company Summary
7.7.2 Kedrion Biopharma Business Overview
7.7.3 Kedrion Biopharma Primary Immunodeficiency Drugs Major Product Offerings
7.7.4 Kedrion Biopharma Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Kedrion Biopharma Key News & Latest Developments
7.8 BPL Inc.
7.8.1 BPL Inc. Company Summary
7.8.2 BPL Inc. Business Overview
7.8.3 BPL Inc. Primary Immunodeficiency Drugs Major Product Offerings
7.8.4 BPL Inc. Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.8.5 BPL Inc. Key News & Latest Developments
7.9 Pharming Group
7.9.1 Pharming Group Company Summary
7.9.2 Pharming Group Business Overview
7.9.3 Pharming Group Primary Immunodeficiency Drugs Major Product Offerings
7.9.4 Pharming Group Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Pharming Group Key News & Latest Developments
7.10 Shire
7.10.1 Shire Company Summary
7.10.2 Shire Business Overview
7.10.3 Shire Primary Immunodeficiency Drugs Major Product Offerings
7.10.4 Shire Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Shire Key News & Latest Developments
7.11 Chengdu Rongsheng Pharmaceutical Co., Ltd
7.11.1 Chengdu Rongsheng Pharmaceutical Co., Ltd Company Summary
7.11.2 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Business Overview
7.11.3 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Major Product Offerings
7.11.4 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Chengdu Rongsheng Pharmaceutical Co., Ltd Key News & Latest Developments
8 Global Primary Immunodeficiency Drugs Production Capacity, Analysis
8.1 Global Primary Immunodeficiency Drugs Production Capacity, 2018-2029
8.2 Primary Immunodeficiency Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Primary Immunodeficiency Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Primary Immunodeficiency Drugs Supply Chain Analysis
10.1 Primary Immunodeficiency Drugs Industry Value Chain
10.2 Primary Immunodeficiency Drugs Upstream Market
10.3 Primary Immunodeficiency Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Primary Immunodeficiency Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Primary Immunodeficiency Drugs in Global Market
Table 2. Top Primary Immunodeficiency Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Primary Immunodeficiency Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Primary Immunodeficiency Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Primary Immunodeficiency Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Primary Immunodeficiency Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Primary Immunodeficiency Drugs Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Primary Immunodeficiency Drugs Product Type
Table 9. List of Global Tier 1 Primary Immunodeficiency Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Primary Immunodeficiency Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Primary Immunodeficiency Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Primary Immunodeficiency Drugs Sales (K Units), 2024-2029
Table 16. By Application – Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Primary Immunodeficiency Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Primary Immunodeficiency Drugs Sales (K Units), 2024-2029
Table 21. By Region – Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Primary Immunodeficiency Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Primary Immunodeficiency Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Primary Immunodeficiency Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Primary Immunodeficiency Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Primary Immunodeficiency Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Primary Immunodeficiency Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Primary Immunodeficiency Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Primary Immunodeficiency Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Primary Immunodeficiency Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Primary Immunodeficiency Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Primary Immunodeficiency Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Primary Immunodeficiency Drugs Sales, (K Units), 2024-2029
Table 46. ADMA Biologics, Inc. Company Summary
Table 47. ADMA Biologics, Inc. Primary Immunodeficiency Drugs Product Offerings
Table 48. ADMA Biologics, Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. ADMA Biologics, Inc. Key News & Latest Developments
Table 50. CSL Behring, LLC Company Summary
Table 51. CSL Behring, LLC Primary Immunodeficiency Drugs Product Offerings
Table 52. CSL Behring, LLC Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. CSL Behring, LLC Key News & Latest Developments
Table 54. Octapharma Company Summary
Table 55. Octapharma Primary Immunodeficiency Drugs Product Offerings
Table 56. Octapharma Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Octapharma Key News & Latest Developments
Table 58. Takeda Pharmaceutical Company Company Summary
Table 59. Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Product Offerings
Table 60. Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Takeda Pharmaceutical Company Key News & Latest Developments
Table 62. Grifols Biologicals, Inc. Company Summary
Table 63. Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Product Offerings
Table 64. Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Grifols Biologicals, Inc. Key News & Latest Developments
Table 66. Baxter Company Summary
Table 67. Baxter Primary Immunodeficiency Drugs Product Offerings
Table 68. Baxter Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Baxter Key News & Latest Developments
Table 70. Kedrion Biopharma Company Summary
Table 71. Kedrion Biopharma Primary Immunodeficiency Drugs Product Offerings
Table 72. Kedrion Biopharma Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Kedrion Biopharma Key News & Latest Developments
Table 74. BPL Inc. Company Summary
Table 75. BPL Inc. Primary Immunodeficiency Drugs Product Offerings
Table 76. BPL Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. BPL Inc. Key News & Latest Developments
Table 78. Pharming Group Company Summary
Table 79. Pharming Group Primary Immunodeficiency Drugs Product Offerings
Table 80. Pharming Group Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Pharming Group Key News & Latest Developments
Table 82. Shire Company Summary
Table 83. Shire Primary Immunodeficiency Drugs Product Offerings
Table 84. Shire Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Shire Key News & Latest Developments
Table 86. Chengdu Rongsheng Pharmaceutical Co., Ltd Company Summary
Table 87. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Product Offerings
Table 88. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Chengdu Rongsheng Pharmaceutical Co., Ltd Key News & Latest Developments
Table 90. Primary Immunodeficiency Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 91. Global Primary Immunodeficiency Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 92. Global Primary Immunodeficiency Drugs Production by Region, 2018-2023 (K Units)
Table 93. Global Primary Immunodeficiency Drugs Production by Region, 2024-2029 (K Units)
Table 94. Primary Immunodeficiency Drugs Market Opportunities & Trends in Global Market
Table 95. Primary Immunodeficiency Drugs Market Drivers in Global Market
Table 96. Primary Immunodeficiency Drugs Market Restraints in Global Market
Table 97. Primary Immunodeficiency Drugs Raw Materials
Table 98. Primary Immunodeficiency Drugs Raw Materials Suppliers in Global Market
Table 99. Typical Primary Immunodeficiency Drugs Downstream
Table 100. Primary Immunodeficiency Drugs Downstream Clients in Global Market
Table 101. Primary Immunodeficiency Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Primary Immunodeficiency Drugs Segment by Type in 2022
Figure 2. Primary Immunodeficiency Drugs Segment by Application in 2022
Figure 3. Global Primary Immunodeficiency Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Primary Immunodeficiency Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Primary Immunodeficiency Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Primary Immunodeficiency Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Primary Immunodeficiency Drugs Revenue in 2022
Figure 9. By Type - Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Primary Immunodeficiency Drugs Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Primary Immunodeficiency Drugs Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Primary Immunodeficiency Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 23. US Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 28. Germany Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 37. China Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Primary Immunodeficiency Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Primary Immunodeficiency Drugs by Region, 2022 VS 2029
Figure 54. Primary Immunodeficiency Drugs Industry Value Chain
Figure 55. Marketing Channels


★調査レポート[世界の原発性免疫不全薬市場予測2023-2029:サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤] (コード:MMG23LY8603)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の原発性免疫不全薬市場予測2023-2029:サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆